
    
      Patients with hepatic insufficiency is an important subgroup of who receive EGFR TKIs. Phase
      I/II studies showed that Icotinib has good security. Based on the above considerations, this
      single-arm, open-label study is designed to evaluate the safety of icotinib 125mg three times
      daily for histologically or cytologically confirmed NSCLC patients with hepatic
      insufficiency.
    
  